Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Quince Therapeutics, Inc.

QNCX ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$33.78

▲ +8.95%

Market Cap $366.17M · Vol 23.68K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$366.17M

Small Cap

Div Yield

N/A

EPS Growth

+97.58%

YoY

RSI (14)

35.84

Momentum

Beta

1.75

vs Market

52W High

$908.00

96.28% below

52W Low

$15.10

123.68% above

Volume

23.68K

Avg 10.90K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

91.31%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Quince Therapeutics, Inc. (QNCX) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does QNCX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.67%

+6.45%

+11.84%

+31.93%

YTD

-94.96%

-89.17%

-81.27%

-98.94%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-83,979,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-77.66% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	+97.58%
Outstanding Shares	10.84M

Technical Indicators

50-Day SMA	$30.99
200-Day SMA	$36.00
RSI (14)	35.84
Beta	1.75
52-Week High	$908.00
52-Week Low	$15.10

Volume Today	23.68K
Avg Daily Volume (30D)	10.90K
Relative Volume	2.17x
Volatility (10D)	76.36
Volatility (30D)	110.94
Free Float	91.31%

Analyst Consensus

BUY

Current Price $33.78

Mean Target $75.00

52W Low$15.10 52W High$908.00

Current

Target

$15.10 $908.00

Current Analyst target

+122.06% upside potential · 7 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00BTK1DS9

ISINUS22053A3059

CountryUSA

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -0.60% ONC BeOne Medicines AG +2.55% 068270.KS Celltrion, Inc. -0.47% MEDP Medpace Holdings, Inc. +3.03% CRL Charles River Laboratories International, Inc. +4.69%

Company Profile

Quince Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is developing a novel disease-modifying therapeutic to address the unmet medical need associated with pulmonary disorders. Its lead asset, LAM-001, a proprietary investigational inhaled dry powder formulation of rapamycin whose differentiated characteristics may permit treatment of pulmonary conditions associated with dysfunctional mammalian target of rapamycin activity. It is evaluating the use of LAM-001 as a treatment for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and for patients with bronchiolitis obliterans syndrome post lung transplant (BOS). It also completed a Phase 2a trial, which enrolled patients with pulmonary arterial hypertension as well as patients with PH-ILD and sarcoidosis associated pulmonary hypertension (SAPH) where it achieved clinically relevant improvement across multiple endpoints, including pulmonary vascular resistance and others.